Free tool
FAERS Monitor: Mytesi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202292 or its brand name (Mytesi, Crofelemer). Reports on generic versions are filed under their own applications.
Reports
239
Serious
84
35% of reports
Hospitalization
33
Death reported
29
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use61
- drug ineffective51
- product dose omission issue29
- diarrhoea26
- death23
- pain17
- anxiety14
- emotional distress14
- anhedonia12
- fatigue11
- chronic kidney disease10
- dizziness10
- constipation9
- depression8
- osteoporosis8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 14 |
| 2022 | 39 |
| 2023 | 43 |
| 2024 | 46 |
| 2025 | 40 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,920 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anhedoniaSignal | 12 | 40.2 | 23.2 | 421 |
| osteoporosisSignal | 8 | 17.1 | 8.7 | 106 |
| chronic kidney diseaseSignal | 10 | 11.6 | 6.3 | 87 |
| emotional distressSignal | 14 | 10.2 | 6.1 | 107 |
| product dose omission issueSignal | 29 | 8.7 | 6.2 | 192 |
| off label useSignal | 61 | 6.1 | 4.9 | 268 |
| anxietySignal | 14 | 4.3 | 2.6 | 33 |
| constipationSignal | 9 | 3.6 | 1.9 | 15 |
| diarrhoeaSignal | 26 | 3.5 | 2.5 | 46 |
| drug ineffectiveSignal | 51 | 3.4 | 2.7 | 90 |
| depressionSignal | 8 | 3.1 | 1.6 | 9 |
| painSignal | 17 | 2.4 | 1.5 | 13 |
| deathSignal | 23 | 2.3 | 1.6 | 17 |
| dizziness | 10 | 1.8 | 1.0 | 3 |
| fatigue | 11 | 1.2 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.